{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:15:12Z","timestamp":1792030512923,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T00:00:00Z","timestamp":1720915200000},"content-version":"am","delay-in-days":317,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.taap.2023.116624","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T17:25:48Z","timestamp":1688577948000},"page":"116624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A mouse model of sensory neuropathy induced by a long course of monomethyl-auristatin E treatment"],"prefix":"10.1016","volume":"474","author":[{"given":"Simon","family":"Frachet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Danigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Duchesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Sturtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Magy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Demiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2023.116624_bb0005","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.18632\/aging.101692","article-title":"Assessing onset, prevalence and survival in mice using a frailty phenotype","volume":"10","author":"Baumann","year":"2018","journal-title":"Aging"},{"key":"10.1016\/j.taap.2023.116624_bb0010","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.neuropharm.2017.08.039","article-title":"Candesartan prevents resiniferatoxin-induced sensory small-fiber neuropathy in mice by promoting angiotensin II-mediated AT2 receptor stimulation","volume":"126","author":"Bessaguet","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.taap.2023.116624_bb0015","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1097\/j.pain.0000000000001361","article-title":"Neuroprotective effect of angiotensin II type 2 receptor stimulation in vincristine-induced mechanical allodynia","volume":"159","author":"Bessaguet","year":"2018","journal-title":"Pain"},{"key":"10.1016\/j.taap.2023.116624_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115534","article-title":"Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): mechanistic insights into MMAE ADC peripheral neuropathy","volume":"421","author":"Best","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2023.116624_bb0025","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-drug conjugate-based therapeutics: state of the science","volume":"111","author":"Birrer","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.taap.2023.116624_bb0030","doi-asserted-by":"crossref","DOI":"10.1186\/1744-8069-10-26","article-title":"A simplified up-down method (SUDO) for measuring mechanical nociception in rodents using von Frey filaments","volume":"10","author":"Bonin","year":"2014","journal-title":"Mol. Pain"},{"key":"10.1016\/j.taap.2023.116624_bb0035","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3390\/pharmaceutics14040848","article-title":"Neuroprotective effect of Ramipril is mediated by AT2 in a mouse MODEL of paclitaxel-induced peripheral neuropathy","volume":"14","author":"Bouchenaki","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.taap.2023.116624_bb0040","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40487-021-00168-y","article-title":"Chemotherapy-induced peripheral neuropathy: epidemiology, Pathomechanisms and treatment","volume":"9","author":"Burgess","year":"2021","journal-title":"Oncol. Ther."},{"key":"10.1016\/j.taap.2023.116624_bb0045","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00280-008-0689-7","article-title":"Interleukin-6 protects against paclitaxel, cisplatin and vincristine-induced neuropathies without impairing chemotherapeutic activity","volume":"62","author":"Callizot","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.taap.2023.116624_bb0050","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3390\/jcm10061332","article-title":"Whole-body pharmacokinetics and physiologically based pharmacokinetic model for monomethyl Auristatin E (MMAE)","volume":"10","author":"Chang","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.taap.2023.116624_bb0055","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bcpt.13654","article-title":"Mechanistic insights into the pathogenesis of microtubule-targeting agent-induced peripheral neuropathy from pharmacogenetic and functional studies","volume":"130","author":"Chua","year":"2022","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.taap.2023.116624_bb0060","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11060-017-2389-9","article-title":"Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of mycosis Fungoides and S\u00e9zary syndrome","volume":"132","author":"Corbin","year":"2017","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.taap.2023.116624_bb0065","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1158\/1078-0432.CCR-12-0290","article-title":"Brentuximab vedotin","volume":"19","author":"Deng","year":"2013","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.taap.2023.116624_bb0070","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"mAbs"},{"key":"10.1016\/j.taap.2023.116624_bb0075","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of Brentuximab Vedotin for CD30 + cutaneous T-cell lymphoma and Lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.taap.2023.116624_bb0080","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vc MMAE, an anti-CD30\u2013monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.taap.2023.116624_bb0085","article-title":"Neuroinflammatory process involved in different preclinical models of chemotherapy-induced peripheral neuropathy","volume":"11","author":"Fumagalli","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.taap.2023.116624_bb0090","first-page":"4413","article-title":"Intraepidermal nerve fibre density in cancer patients receiving adjuvant chemotherapy","volume":"31","author":"Koskinen","year":"2011","journal-title":"Anticancer Res."},{"key":"10.1016\/j.taap.2023.116624_bb0095","first-page":"747","article-title":"EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy","volume":"12","author":"Lauria","year":"2005","journal-title":"Eur. J. Neurol. Off. J. Eur. Fed. Neurol. Soc."},{"key":"10.1016\/j.taap.2023.116624_bb0100","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/psp4.12192","article-title":"Time-to-event analysis of Polatuzumab Vedotin-induced peripheral neuropathy to assist in the comparison of clinical dosing regimens: time-to-event analysis","volume":"6","author":"Lu","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.taap.2023.116624_bb0105","series-title":"Current Protocols in Neuroscience","article-title":"Models of nociception: hot-plate, tail-Flick, and formalin tests in rodents","author":"Malmberg","year":"2001"},{"key":"10.1016\/j.taap.2023.116624_bb0110","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1038\/bcj.2015.72","article-title":"Brentuximab vedotin: axonal microtubule\u2019s Apollyon","volume":"5","author":"Mariotto","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.taap.2023.116624_bb0115","article-title":"Reporting animal research: explanation and elaboration for the ARRIVE guidelines 2.0","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol."},{"key":"10.1016\/j.taap.2023.116624_bb0120","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.taap.2023.116624_bb0125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/ar.1092150111","article-title":"Fiber composition of the rat sciatic nerve","volume":"215","author":"Schmalbruch","year":"1986","journal-title":"Anat. Rec."},{"key":"10.1016\/j.taap.2023.116624_bb0130","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.taap.2023.116624_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yrtph.2016.10.012","article-title":"Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: challenges and perspectives in translatability from nonclinical toxicology studies to the clinic","volume":"82","author":"Stagg","year":"2016","journal-title":"Regul. Toxicol. Pharmacol. RTP"},{"key":"10.1016\/j.taap.2023.116624_bb0140","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1091581819894281","article-title":"Predictivity\/translatability of toxicities observed in nonclinical toxicology studies to clinical safety outcomes in drug development: case examples","volume":"39","author":"Stagg","year":"2020","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.taap.2023.116624_bb0145","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.3390\/cancers13236125","article-title":"Brentuximab-induced peripheral neurotoxicity: a multidisciplinary approach to manage an emerging challenge in Hodgkin lymphoma therapy","volume":"13","author":"Velasco","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.taap.2023.116624_bb0150","first-page":"3736","article-title":"The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin\u2019s disease","volume":"62","author":"Wahl","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.taap.2023.116624_bb0155","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100001","article-title":"Zilovertamab Vedotin targeting of ROR1 as therapy for lymphoid cancers","volume":"1","author":"Wang","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.taap.2023.116624_bb0160","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1158\/0008-5472.CAN-17-1467","article-title":"Peripheral neuropathy induced by microtubule-targeted chemotherapies: insights into acute injury and long-term recovery","volume":"78","author":"Wozniak","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.taap.2023.116624_bb0165","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.3390\/jcm10061323","article-title":"Preclinical characterization of the distribution, catabolism, and elimination of a Polatuzumab Vedotin-Piiq (POLIVY\u00ae) antibody-drug conjugate in Sprague Dawley rats","volume":"10","author":"Yip","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.taap.2023.116624_bb0170","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab Vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N. Engl. J. Med."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X23002636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X23002636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:04:24Z","timestamp":1758575064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X23002636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":34,"alternative-id":["S0041008X23002636"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2023.116624","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A mouse model of sensory neuropathy induced by a long course of monomethyl-auristatin E treatment","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2023.116624","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116624"}}